Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Bladder Cancer

  Free Subscription


Articles published in Eur Urol

Retrieve available abstracts of 124 articles:
HTML format
Text format



Single Articles


    April 2018
  1. MOSCHINI M, Sargos P
    Re: Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy a Randomized Phase 2 Trial.
    Eur Urol. 2018 Apr 9. pii: S0302-2838(18)30203.
    PubMed     Text format    


  2. FABA OR, Breda A, Palou J
    Re: Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
    Eur Urol. 2018 Apr 7. pii: S0302-2838(18)30243.
    PubMed     Text format    


    March 2018
  3. SARFATY M, Hall PS, Chan KKW, Virik K, et al
    Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
    Eur Urol. 2018 Mar 22. pii: S0302-2838(18)30182.
    PubMed     Text format     Abstract available


  4. CUMBERBATCH MGK, Foerster B, Catto JWF, Kamat AM, et al
    Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review.
    Eur Urol. 2018 Mar 6. pii: S0302-2838(18)30121.
    PubMed     Text format     Abstract available


    February 2018
  5. EL-ACHKAR A, Kassouf W
    Re: Propensity Score Analysis of Radical Cystectomy Versus Bladder-sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Eur Urol. 2018 Feb 14. pii: S0302-2838(18)30088.
    PubMed     Text format    


    December 2017
  6. SAITO R, Kobayashi T, Ogawa O
    Re: Comprehensive Molecular Characterization of Muscle-invasive Bladder Cancer.
    Eur Urol. 2017 Dec 20. pii: S0302-2838(17)31042.
    PubMed     Text format    


  7. PANG KH, Noon AP
    Re: Radical Cystectomy (Bladder Removal) Against Intravesical BCG Immunotherapy for High-risk Non-muscle Invasive Bladder Cancer (BRAVO): A Protocol for a Randomised Controlled Feasibility Study.
    Eur Urol. 2017 Dec 19. pii: S0302-2838(17)31039.
    PubMed     Text format    


  8. OOSTERLINCK W, Decaestecker K
    Re: Active Surveillance for Low-risk Nonmuscle Invasive Bladder Cancer (NMIBC): a Confirmatory and Resource Consumption Study from Bladder Cancer Italian Active Surveillance (BIAS) Project.
    Eur Urol. 2017 Dec 7. pii: S0302-2838(17)31018.
    PubMed     Text format    


  9. CUMBERBATCH MG, Catto JWF
    Re: Comprehensive Molecular Characterization of Muscle Invasive Bladder Cancer.
    Eur Urol. 2017 Dec 5. pii: S0302-2838(17)31007.
    PubMed     Text format    


    November 2017
  10. ODDENS JR, de Reijke TM
    The Current State of Predicting Response on Bacillus Calmette-Guerin Treatment for Nonmuscle Invasive Bladder Cancer is Not Yet Useful for Patients but Attributes to Understanding Its Mechanisms of Action.
    Eur Urol. 2017 Nov 30. pii: S0302-2838(17)31006.
    PubMed     Text format    


  11. CHOI W, McConkey D
    Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in The Cancer Genome Atl
    Eur Urol. 2017 Nov 23. pii: S0302-2838(17)30979.
    PubMed     Text format    


  12. LINSCOTT JA, Smith AB, Sammon JD
    Re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354-65.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30971.
    PubMed     Text format    


  13. ABUFARAJ M, Dalbagni G, Daneshmand S, Horenblas S, et al
    The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review.
    Eur Urol. 2017 Nov 6. pii: S0302-2838(17)30840.
    PubMed     Text format     Abstract available


    October 2017
  14. MAIA MC, Grivas P, Agarwal N, Pal SK, et al
    Circulating Tumor DNA in Bladder Cancer: Novel Applications and Future Directions.
    Eur Urol. 2017 Oct 30. pii: S0302-2838(17)30902.
    PubMed     Text format    


    September 2017
  15. OHNO Y
    Re: Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer.
    Eur Urol. 2017 Sep 26. pii: S0302-2838(17)30780.
    PubMed     Text format    


  16. BIRKENKAMP-DEMTRODER K, Christensen E, Nordentoft I, Knudsen M, et al
    Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis.
    Eur Urol. 2017 Sep 25. pii: S0302-2838(17)30775.
    PubMed     Text format     Abstract available


    August 2017
  17. LEOW JJ, Cole AP, Seisen T, Bellmunt J, et al
    Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA.
    Eur Urol. 2017 Aug 9. pii: S0302-2838(17)30640.
    PubMed     Text format     Abstract available


    July 2017
  18. BOSSCHIETER J, Nieuwenhuijzen JA, van Ginkel T, Vis AN, et al
    Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
    Eur Urol. 2017 Jul 10. pii: S0302-2838(17)30538.
    PubMed     Text format     Abstract available


    June 2017
  19. SAFIRI S, Ayubi E
    Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Expe
    Eur Urol. 2017 Jun 22. pii: S0302-2838(17)30503.
    PubMed     Text format    


  20. GIACALONE NJ, Niemierko A, Shipley WU, Efstathiou JA, et al
    Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: A
    Eur Urol. 2017 Jun 19. pii: S0302-2838(17)30502.
    PubMed     Text format    


  21. BOSSCHIETER J, Vis AN, van der Poel HG, Moonen LM, et al
    Robot-assisted Laparoscopic Implantation of Brachytherapy Catheters in Bladder Cancer.
    Eur Urol. 2017 Jun 12. pii: S0302-2838(17)30494.
    PubMed     Text format     Abstract available


  22. POWLES T, Gomez de Liano A, Ackerman C
    Reply to Pontus Eriksson, Gottfrid Sjodahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First
    Eur Urol. 2017 Jun 9. pii: S0302-2838(17)30453.
    PubMed     Text format    


  23. D'ANDREA D, Shariat SF
    Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement.
    Eur Urol. 2017 Jun 6. pii: S0302-2838(17)30481.
    PubMed     Text format    


  24. DYRSKJOT L, Reinert T, Algaba F, Christensen E, et al
    Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
    Eur Urol. 2017 Jun 2. pii: S0302-2838(17)30475.
    PubMed     Text format     Abstract available


  25. PIETZAK EJ, Bagrodia A, Cha EK, Drill EN, et al
    Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    Eur Urol. 2017 Jun 2. pii: S0302-2838(17)30466.
    PubMed     Text format     Abstract available


  26. CHEVALIER MF, Bohner P, Pieraerts C, Lhermitte B, et al
    Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer.
    Eur Urol. 2017;71:854-857.
    PubMed     Text format     Abstract available


  27. WANG L, Sustic T, Leite de Oliveira R, Lieftink C, et al
    A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Eur Urol. 2017;71:858-862.
    PubMed     Text format     Abstract available


    May 2017
  28. ERIKSSON P, Sjodahl G, Liedberg F
    Re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30455.
    PubMed     Text format    


  29. SEISEN T, Cole AP, Trinh QD
    Reply from Authors re: Girish S. Kulkarni, Zachary Klaassen. Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details? Eur Urol. In press. http://doi.
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30411.
    PubMed     Text format    


  30. KULKARNI GS, Klaassen Z
    Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details?
    Eur Urol. 2017 May 5. pii: S0302-2838(17)30338.
    PubMed     Text format    


  31. BABJUK M
    Bladder Cancer in the Elderly.
    Eur Urol. 2017 May 3. pii: S0302-2838(17)30326.
    PubMed     Text format    


  32. FONTEYNE V, Ost P, Bellmunt J, Droz JP, et al
    Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.
    Eur Urol. 2017 May 3. pii: S0302-2838(17)30230.
    PubMed     Text format     Abstract available


  33. COLLINS JW, Hosseini A, Adding C, Nyberg T, et al
    Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group.
    Eur Urol. 2017;71:723-726.
    PubMed     Text format     Abstract available


    April 2017
  34. SOUKUP V, Capoun O, Cohen D, Hernandez V, et al
    Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel
    Eur Urol. 2017 Apr 27. pii: S0302-2838(17)30323.
    PubMed     Text format     Abstract available


  35. GALSKY MD, Sfakianos JP, Ferket BS
    Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Are Things Now Getting Personal?
    Eur Urol. 2017 Apr 19. pii: S0302-2838(17)30292.
    PubMed     Text format    


  36. BLACK PC
    Seeking the Molecular Truth in Bladder Cancer: Biology=Genomex(Transcriptome)2.
    Eur Urol. 2017 Apr 17. pii: S0302-2838(17)30286.
    PubMed     Text format    


  37. SEILER R, Oo HZ, Tortora D, Clausen TM, et al
    An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
    Eur Urol. 2017 Apr 10. pii: S0302-2838(17)30232.
    PubMed     Text format     Abstract available


  38. SEILER R, Ashab HA, Erho N, van Rhijn BW, et al
    Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
    Eur Urol. 2017 Apr 5. pii: S0302-2838(17)30251.
    PubMed     Text format     Abstract available


  39. GAKIS G, Black PC, Bochner BH, Boorjian SA, et al
    Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy.
    Eur Urol. 2017;71:545-557.
    PubMed     Text format     Abstract available


    March 2017
  40. CHOI W, Ochoa A, McConkey DJ, Aine M, et al
    Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.
    Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30175.
    PubMed     Text format     Abstract available


  41. BOKARICA P, Hrkac A, Gilja I
    Re: J. Alfred Witjes, Thierry Lebret, Eva M. Comperat, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol 2017;71:462-75.
    Eur Urol. 2017 Mar 6. pii: S0302-2838(17)30126.
    PubMed     Text format    


  42. DY GW, Gore JL, Forouzanfar MH, Naghavi M, et al
    Global Burden of Urologic Cancers, 1990-2013.
    Eur Urol. 2017;71:437-446.
    PubMed     Text format     Abstract available


  43. BABJUK M, Bohle A, Burger M, Capoun O, et al
    EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Eur Urol. 2017;71:447-461.
    PubMed     Text format     Abstract available


    February 2017
  44. MAY M, Lebentrau S, Brookman-May SD
    Re: Decreased Overall and Bladder Cancer-specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis.
    Eur Urol. 2017 Feb 20. pii: S0302-2838(17)30107.
    PubMed     Text format    


  45. COTTE J, Roupret M
    Re: Long-term Oncological Outcomes of an Active Surveillance Program in Recurrent Low Grade Ta Bladder Cancer.
    Eur Urol. 2017 Feb 18. pii: S0302-2838(17)30106.
    PubMed     Text format    


  46. MARQUES M, Real FX
    PIcKing on Fibroblast Growth Factor Receptors as Bladder Cancer Therapeutic Targets.
    Eur Urol. 2017 Feb 14. pii: S0302-2838(17)30087.
    PubMed     Text format    


    January 2017
  47. ROTH B
    Re: Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures.
    Eur Urol. 2017 Jan 13. pii: S0302-2838(17)30012.
    PubMed     Text format    


  48. GIACALONE NJ, Shipley WU, Clayman RH, Niemierko A, et al
    Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Eur Urol. 2017 Jan 9. pii: S0302-2838(16)30924.
    PubMed     Text format     Abstract available


  49. DE VERE WHITE R
    Re: Management of Nonmuscle Invasive Bladder Cancer: A Comprehensive Analysis of Guidelines from the Unites States, Europe, and Asia.
    Eur Urol. 2017 Jan 7. pii: S0302-2838(16)30921.
    PubMed     Text format    


  50. CHRISTENSEN E, Birkenkamp-Demtroder K, Nordentoft I, Hoyer S, et al
    Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
    Eur Urol. 2017 Jan 6. pii: S0302-2838(16)30920.
    PubMed     Text format     Abstract available


    December 2016
  51. SELINSKI S, Gerullis H, Otto T, Roth E, et al
    Ultra-slow N-Acetyltransferase 2 Is Associated with Recurrence-free Time in Bladder Cancer Patients.
    Eur Urol. 2016 Dec 28. pii: S0302-2838(16)30904.
    PubMed     Text format    


    October 2016
  52. LIEDBERG F, Jancke G, Sorenby A, Kannisto P, et al
    Should we Refrain from Performing Oophorectomy in Conjunction with Radical Cystectomy for Bladder Cancer?
    Eur Urol. 2016 Oct 19. pii: S0302-2838(16)30713.
    PubMed     Text format     Abstract available


  53. NECCHI A, Giardiello D, Mariani L
    Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer.
    Eur Urol. 2016 Oct 6. pii: S0302-2838(16)30684.
    PubMed     Text format    


    September 2016
  54. LUO HL, Chen YT, Cheng YT, Chiang PH, et al
    Re: Thomas Seisen, Benoit Peyronnet, Jose Luis Dominguez-Escrig, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Can
    Eur Urol. 2016 Sep 26. pii: S0302-2838(16)30663.
    PubMed     Text format    


  55. SEISEN T, Babjuk M, Roupret M
    Reply to Hao Lun Luo, Yen Ta Chen, Yuan Tso Cheng, and Po Hui Chiang's Letter to the Editor re: Re: Thomas Seisen, Benoit Peyronnet, Jose Luis Dominguez-Escrig, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for
    Eur Urol. 2016 Sep 22. pii: S0302-2838(16)30662.
    PubMed     Text format    


    August 2016
  56. LONGO T, McGinley KF, Freedman JA, Etienne W, et al
    Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer.
    Eur Urol. 2016 Aug 9. pii: S0302-2838(16)30463.
    PubMed     Text format     Abstract available


    July 2016
  57. SEISEN T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, et al
    Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephrourecterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel.
    Eur Urol. 2016 Jul 28. pii: S0302-2838(16)30419.
    PubMed     Text format     Abstract available


  58. ARENDS TJ, Witjes JA
    Reply to Slawomir Poletajew, Piotr Radziszewski, Juan Palou Letter to the Editor re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Baci
    Eur Urol. 2016 Jul 14. pii: S0302-2838(16)30395.
    PubMed     Text format    


  59. POLETAJEW S, Radziszewski P, Palou J
    Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and Hi
    Eur Urol. 2016 Jul 11. pii: S0302-2838(16)30394.
    PubMed     Text format    


  60. BABJUK M
    Trends in Bladder Cancer Incidence and Mortality: Success or Disappointment?
    Eur Urol. 2016 Jul 11. pii: S0302-2838(16)30392.
    PubMed     Text format    


  61. YANG Z, Li C, Liu H, Zhang X, et al
    Single-cell sequencing reveals variants in ARID1A, GPRC5A and MLL2 driving self-renewal of human bladder cancer stem cells.
    Eur Urol. 2016 Jul 4. pii: S0302-2838(16)30343.
    PubMed     Text format     Abstract available


  62. YOSSEPOWITCH O
    Re: Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer.
    Eur Urol. 2016;70:204.
    PubMed     Text format    


    June 2016
  63. ALFRED WITJES J, Lebret T, Comperat EM, Cowan NC, et al
    Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.
    Eur Urol. 2016 Jun 30. pii: S0302-2838(16)30290.
    PubMed     Text format     Abstract available


  64. ANTONI S, Ferlay J, Soerjomataram I, Znaor A, et al
    Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.
    Eur Urol. 2016 Jun 28. pii: S0302-2838(16)30280.
    PubMed     Text format     Abstract available


  65. HERMANS TJ, Mertens LS, van Rhijn BW
    Re: Trends in the Use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-invasive Bladder Cancer: A Sign of Changing Tides.
    Eur Urol. 2016;69:1156-7.
    PubMed     Text format    


    May 2016
  66. MCKIERNAN J
    Bacillus Calmette-Guerin Failure in Non-muscle-invasive Bladder Cancer: One Size Does Not Fit All.
    Eur Urol. 2016 May 4. pii: S0302-2838(16)30033.
    PubMed     Text format    


  67. WITJES JA
    Re: Trends in the Use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-invasive Bladder Cancer: A Sign of Changing Tides.
    Eur Urol. 2016;69:963.
    PubMed     Text format    


    April 2016
  68. CUMBERBATCH MG, Catto JW
    Micropapillary Variant Bladder Cancer: A Bad Apple or a New Fruit?
    Eur Urol. 2016 Apr 29. pii: S0302-2838(16)30066.
    PubMed     Text format    


  69. NAITO S, Algaba F, Babjuk M, Bryan RT, et al
    The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Mus
    Eur Urol. 2016 Apr 22. pii: S0302-2838(16)30031.
    PubMed     Text format     Abstract available


  70. GRAY PJ, Efstathiou JA, Shipley WU
    Re: Radical Cystectomy vs. Chemoradiation in T2-4aN0M0 Bladder Cancer: A Case-control Study.
    Eur Urol. 2016;69:757-8.
    PubMed     Text format    


  71. PICKARD R
    Is Robot-assisted Cystectomy Better than Open?--Nearing an Answer after a Decade of Use.
    Eur Urol. 2016;69:622-3.
    PubMed     Text format    


  72. KHAN MS, Gan C, Ahmed K, Ismail AF, et al
    A Single-centre Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).
    Eur Urol. 2016;69:613-21.
    PubMed     Text format     Abstract available


    March 2016
  73. GUO CC, Dadhania V, Zhang L, Majewski T, et al
    Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.
    Eur Urol. 2016 Mar 14. pii: S0302-2838(16)00246.
    PubMed     Text format     Abstract available


  74. RENTSCH CA, Muller DC, Ruiz C, Bubendorf L, et al
    Moving Towards Minimally Invasive Genomically Based Diagnosis and Monitoring of Bladder Cancer.
    Eur Urol. 2016 Mar 4. pii: S0302-2838(16)00240.
    PubMed     Text format    


  75. ROUPRET M
    Re: Finasteride Reduces the Risk of Bladder Cancer in a Large Prospective Screening Study.
    Eur Urol. 2016;69:537.
    PubMed     Text format    


  76. SHIBING Y, Qiang W
    Re: Morgan Roupret, Marko Babjuk, Eva Comperat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868-79.
    Eur Urol. 2016;69:e49-50.
    PubMed     Text format    


  77. ROUPRET M
    Reply to Yan Shibing and Wei Qiang's Letter to the Editor re: Morgan Roupret, Marko Babjuk, Eva Comperat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868-79.
    Eur Urol. 2016;69:e51-2.
    PubMed     Text format    


  78. HAMILTON-REEVES JM, Bechtel MD, Hand LK, Schleper A, et al
    Effects of Immunonutrition for Cystectomy on Immune Response and Infection Rates: A Pilot Randomized Controlled Clinical Trial.
    Eur Urol. 2016;69:389-92.
    PubMed     Text format     Abstract available


    February 2016
  79. MMEJE CO, Guo CC, Shah JB, Navai N, et al
    Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guerin Therapy: Implication for Clinical Trial Design.
    Eur Urol. 2016 Feb 24. pii: S0302-2838(16)00209.
    PubMed     Text format     Abstract available


  80. WILLIAMS SB, Kamat AM
    Re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patien
    Eur Urol. 2016 Feb 10. pii: S0302-2838(16)00173.
    PubMed     Text format    


  81. SYLVESTER R, Gontero P, Oddens J
    Reply to Stephen B. Williams and Ashish M. Kamat's Letter to the Editor re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Surv
    Eur Urol. 2016 Feb 10. pii: S0302-2838(16)00175.
    PubMed     Text format    


  82. SOAVE A, Rink M
    Words of Wisdom. Re: Vinflunine in Routine Clinical Practice for the Treatment of Advanced or Metastatic Urothelial Cell Carcinoma--Data from a Prospective, Multicenter Experience.
    Eur Urol. 2016;69:373-4.
    PubMed     Text format    


  83. KAMAT AM, Urbauer DL
    Reply from Authors re: Tahlita C.M. Zuiverloon, Ellen C. Zwarthoff. Predicting Response to Intravesical Bacillus Calmette-Guerin Immunotherapy: Are We Moving Forward? Eur Urol 2016;69:201-2: The Goal: Individualized Bacillus Calmette-Guerin Therapy.
    Eur Urol. 2016;69:203.
    PubMed     Text format    


  84. WITJES JA
    The Final Answer to the Question of Whether We Should Use a Single Postoperative Instillation of Chemotherapy After Resection of pTa and pT1 Bladder Tumors.
    Eur Urol. 2016;69:245-6.
    PubMed     Text format    


  85. ZUIVERLOON TC, Zwarthoff EC
    Predicting Response to Intravesical Bacillus Calmette-Guerin Immunotherapy: Are We Moving Forward?
    Eur Urol. 2016;69:201-2.
    PubMed     Text format    


  86. SATKUNASIVAM R, Santomauro M, Chopra S, Plotner E, et al
    Robotic Intracorporeal Orthotopic Neobladder: Urodynamic Outcomes, Urinary Function, and Health-related Quality of Life.
    Eur Urol. 2016;69:247-53.
    PubMed     Text format     Abstract available


  87. KAMAT AM, Briggman J, Urbauer DL, Svatek R, et al
    Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guerin.
    Eur Urol. 2016;69:197-200.
    PubMed     Text format     Abstract available


  88. SYLVESTER RJ, Oosterlinck W, Holmang S, Sydes MR, et al
    Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carci
    Eur Urol. 2016;69:231-44.
    PubMed     Text format     Abstract available


    January 2016
  89. BIRKENKAMP-DEMTRODER K, Nordentoft I, Christensen E, Hoyer S, et al
    Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.
    Eur Urol. 2016 Jan 20. pii: S0302-2838(16)00058.
    PubMed     Text format     Abstract available


  90. ARENDS TJ, Nativ O, Maffezzini M, de Cobelli O, et al
    Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Eur Urol. 2016 Jan 20. pii: S0302-2838(16)00057.
    PubMed     Text format     Abstract available


    December 2015
  91. KIM JH, Ku JH
    Re: Edwin E. Morales, Sonja Grill, Robert S. Svatek, et al. Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.08.029.
    Eur Urol. 2015 Dec 9. pii: S0302-2838(15)01174.
    PubMed     Text format    


  92. OHLMANN CH, Stockle M
    Comment re: Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3
    Eur Urol. 2015;68:1104-5.
    PubMed     Text format    


    November 2015
  93. RESNICK MJ
    Variation in Bladder Cancer Spending: A Global Call to Action.
    Eur Urol. 2015 Nov 19. pii: S0302-2838(15)01084.
    PubMed     Text format    


    October 2015
  94. LEAL J, Luengo-Fernandez R, Sullivan R, Witjes JA, et al
    Economic Burden of Bladder Cancer Across the European Union.
    Eur Urol. 2015 Oct 24. pii: S0302-2838(15)01005.
    PubMed     Text format     Abstract available


    September 2015
  95. SONPAVDE G, Pond GR, Bellmunt J
    Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer - At What Cost? Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.08.039: Combination Chemotherapy as a
    Eur Urol. 2015 Sep 23. pii: S0302-2838(15)00909.
    PubMed     Text format    


  96. SONPAVDE G, Nix JW
    The Neoadjuvant Paradigm for Development of Systemic Therapy and Precision Medicine for Bladder Cancer.
    Eur Urol. 2015 Sep 20. pii: S0302-2838(15)00912.
    PubMed     Text format    


  97. LA VECCHIA C
    Finasteride and Bladder Cancer.
    Eur Urol. 2015 Sep 10. pii: S0302-2838(15)00858.
    PubMed     Text format    


  98. ROSE TL, Milowsky MI
    A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer - At What Cost?
    Eur Urol. 2015 Sep 4. pii: S0302-2838(15)00784.
    PubMed     Text format    


  99. DOBRUCH J, Daneshmand S, Fisch M, Lotan Y, et al
    Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes.
    Eur Urol. 2015 Sep 4. pii: S0302-2838(15)00782.
    PubMed     Text format     Abstract available


    August 2015
  100. MORALES EE, Grill S, Svatek RS, Kaushik D, et al
    Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study.
    Eur Urol. 2015 Aug 27. pii: S0302-2838(15)00772.
    PubMed     Text format     Abstract available


  101. RENTSCH CA, Stenner F, Ruiz C, Bubendorf L, et al
    Three Genes to Predict Response to Chemotherapy for Bladder Cancer: Individualised Cancer Care at the Doorstep.
    Eur Urol. 2015 Aug 13. pii: S0302-2838(15)00709.
    PubMed     Text format    


  102. BLACK PC
    Fine-tuning Risk Stratification for Non-Muscle-invasive Bladder Cancer.
    Eur Urol. 2015 Aug 6. pii: S0302-2838(15)00693.
    PubMed     Text format    


    July 2015
  103. PLIMACK ER, Dunbrack RL, Brennan TA, Andrake MD, et al
    Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based chemotherapy in Muscle-invasive Bladder Cancer.
    Eur Urol. 2015 Jul 31. pii: S0302-2838(15)00613.
    PubMed     Text format     Abstract available


  104. AINE M, Eriksson P, Liedberg F, Hoglund M, et al
    On Molecular Classification of Bladder Cancer: Out of One, Many.
    Eur Urol. 2015 Jul 24. pii: S0302-2838(15)00666.
    PubMed     Text format     Abstract available


  105. CAMBIER S, Sylvester RJ, Collette L, Gontero P, et al
    EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin.
    Eur Urol. 2015 Jul 22. pii: S0302-2838(15)00556.
    PubMed     Text format     Abstract available


  106. FROEHNER M, Koch R, Heberling U, Novotny V, et al
    Decreased Overall and Bladder Cancer-Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis.
    Eur Urol. 2015 Jul 17. pii: S0302-2838(15)00564.
    PubMed     Text format     Abstract available


  107. NGUYEN DP, Scherr DS
    Reply to Farshad Pourmalek, Hamidreza Abdi, and Peter C. Black's Letter to the Editor re: Daniel P. Nguyen, Bashir Al Hussein Al Awamlh, Xian Wu, et al. Recurrence Patterns After Open and Robot-assisted Radical Cystectomy for Bladder Cancer. Eur Urol.
    Eur Urol. 2015 Jul 14. pii: S0302-2838(15)00558.
    PubMed     Text format    


  108. POURMALEK F, Abdi H, Black PC
    Re: Daniel P. Nguyen, Bashir Al Hussein Al Awamlh, Xian Wu, et al. Recurrence Patterns After Open and Robot-assisted Radical Cystectomy for Bladder Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.02.003.
    Eur Urol. 2015 Jul 13. pii: S0302-2838(15)00559.
    PubMed     Text format    


  109. GOFRIT ON
    Re: Long-Term Outcomes in Patients with Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233.
    Eur Urol. 2015;68:165-6.
    PubMed     Text format    


  110. PALMA N, Morris JC, Ali SM, Ross JS, et al
    Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.
    Eur Urol. 2015;68:168-70.
    PubMed     Text format    


    June 2015
  111. DE MARTINO M, Lucca I, Mbeutcha A, Wiener HG, et al
    Carbonic Anhydrase IX as a Diagnostic Urinary Marker for Urothelial Bladder Cancer.
    Eur Urol. 2015 Jun 29. pii: S0302-2838(15)00518.
    PubMed     Text format     Abstract available


  112. GIANNARINI G, Palumbo V, Ficarra V
    Words of Wisdom. Re: robotic intracorporeal orthotopic neobladder during radical cystectomy in 132 patients.
    Eur Urol. 2015;67:1191-2.
    PubMed     Text format    


    April 2015
  113. HERR HW
    Reply from Author re: Peter C. Black. Narrowing the cystoscopy gap. Eur Urol 2015;67:609-10: A better transurethral resection--proved or not!
    Eur Urol. 2015;67:610-1.
    PubMed     Text format    


  114. BLACK PC
    Narrowing the cystoscopy gap.
    Eur Urol. 2015;67:609-10.
    PubMed     Text format    


  115. HERR HW
    Randomized trial of narrow-band versus white-light cystoscopy for restaging (second-look) transurethral resection of bladder tumors.
    Eur Urol. 2015;67:605-8.
    PubMed     Text format     Abstract available


    March 2015
  116. CHAN KG, Guru K, Wiklund P, Catto J, et al
    Robot-assisted radical cystectomy and urinary diversion: technical recommendations from the Pasadena Consensus Panel.
    Eur Urol. 2015;67:423-31.
    PubMed     Text format     Abstract available


  117. ARON M, Gill IS
    Robotic radical cystectomy: so far, so good--what next?
    Eur Urol. 2015;67:361-2.
    PubMed     Text format    


  118. WILSON TG, Guru K, Rosen RC, Wiklund P, et al
    Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel.
    Eur Urol. 2015;67:363-75.
    PubMed     Text format     Abstract available


  119. NOVARA G, Catto JW, Wilson T, Annerstedt M, et al
    Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy.
    Eur Urol. 2015;67:376-401.
    PubMed     Text format     Abstract available


  120. YUH B, Wilson T, Bochner B, Chan K, et al
    Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy.
    Eur Urol. 2015;67:402-22.
    PubMed     Text format     Abstract available


    February 2015
  121. JONES RJ
    Making trials work in practice: please mind the gap.
    Eur Urol. 2015;67:250-1.
    PubMed     Text format    


  122. VAN DER HEIJDEN MS, van Rhijn BW
    The molecular background of urothelial cancer: ready for action?
    Eur Urol. 2015;67:202-3.
    PubMed     Text format    


  123. KIM PH, Cha EK, Sfakianos JP, Iyer G, et al
    Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.
    Eur Urol. 2015;67:198-201.
    PubMed     Text format     Abstract available


    January 2015
  124. NAVAI N, Matin SF
    Words of wisdom. Re: A randomized trial of robot-assisted laparoscopic radical cystectomy.
    Eur Urol. 2015;67:173-4.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: